NASDAQ · ATRA
Healthcare · Biotechnology
$9.70
Up+$0.32 (+3.41%)
Updated Aug 22, 2026, 8:40 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ATRA closed at $9.70 after 21 trading sessions, up 22.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $9.46 | $9.89 | $9.15 | $9.70 | 27.09K |
| Aug 20, 2026 | $9.60 | $9.74 | $9.14 | $9.38 | 28.02K |
| Aug 19, 2026 | $8.85 | $9.74 | $8.2764 | $9.60 | 79.15K |
| Aug 18, 2026 | $8.34 | $8.90 | $8.34 | $8.72 | 29.5K |
| Aug 17, 2026 | $8.00 | $8.48 | $7.81 | $8.36 | 66.1K |
| Aug 14, 2026 | $8.51 | $8.51 | $7.99 | $8.09 | 66.25K |
| Aug 13, 2026 | $8.34 | $9.24 | $7.73 | $8.51 | 126.52K |
| Aug 12, 2026 | $8.88 | $9.43 | $8.70 | $9.225 | 90K |
| Aug 11, 2026 | $8.62 | $9.04 | $8.359 | $8.94 | 29.25K |
| Aug 10, 2026 | $8.42 | $8.80 | $8.09 | $8.61 | 45.33K |
| Aug 7, 2026 | $8.30 | $8.485 | $8.2015 | $8.45 | 23.21K |
| Aug 6, 2026 | $8.60 | $8.645 | $8.0901 | $8.25 | 22.86K |
| Aug 5, 2026 | $8.60 | $8.98 | $8.3801 | $8.54 | 32.52K |
| Aug 4, 2026 | $8.55 | $9.11 | $8.55 | $8.77 | 42.28K |
| Aug 3, 2026 | $8.42 | $8.6599 | $8.255 | $8.55 | 53.24K |
| Jul 31, 2026 | $8.17 | $8.6699 | $7.86 | $8.38 | 34.5K |
| Jul 30, 2026 | $8.18 | $8.32 | $7.86 | $8.17 | 96.04K |
| Jul 29, 2026 | $7.74 | $8.25 | $7.57 | $8.06 | 39.85K |
| Jul 28, 2026 | $7.76 | $7.9099 | $7.39 | $7.81 | 85.37K |
| Jul 27, 2026 | $8.06 | $8.3305 | $7.65 | $7.71 | 62.72K |
| Jul 24, 2026 | $8.19 | $8.38 | $7.84 | $7.90 | 75.24K |
The latest Smart Investors Daily articles mentioning ATRA.
ATRA research
Company profile and research snapshot.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2026 | Freedom Broker | Hold | — |
| May 8, 2026 | Canaccord Genuity | Buy | — |
| Jan 13, 2026 | Canaccord Genuity | Hold | — |
| Dec 19, 2025 | Canaccord Genuity | Buy | — |
| Mar 11, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Finnhub · May 17, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara...
Finnhub · May 15, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara...
Finnhub · May 12, 2026
Atara Biotherapeutics Inc: Atara Biotherapeutics Inc - may offer up to $79.27 million in common stock as of May 12, 2026 - SEC filing...
Benzinga · May 12, 2026
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ATRA.
